PXMD vs. KZIA, SONN, FWBI, IBIO, SNPX, HOTH, KTRA, PTIX, YMTX, and KA
Should you be buying PaxMedica stock or one of its competitors? The main competitors of PaxMedica include Kazia Therapeutics (KZIA), Sonnet BioTherapeutics (SONN), First Wave BioPharma (FWBI), iBio (IBIO), Synaptogenix (SNPX), Hoth Therapeutics (HOTH), Kintara Therapeutics (KTRA), Protagenic Therapeutics (PTIX), Yumanity Therapeutics (YMTX), and Kineta (KA). These companies are all part of the "pharmaceutical preparations" industry.
Kazia Therapeutics (NASDAQ:KZIA) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, community ranking, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.
In the previous week, PaxMedica had 2 more articles in the media than Kazia Therapeutics. MarketBeat recorded 3 mentions for PaxMedica and 1 mentions for Kazia Therapeutics. Kazia Therapeutics' average media sentiment score of 0.58 beat PaxMedica's score of -0.37 indicating that PaxMedica is being referred to more favorably in the news media.
Kazia Therapeutics has higher revenue and earnings than PaxMedica.
Kazia Therapeutics has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, PaxMedica has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500.
30.9% of Kazia Therapeutics shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 1.0% of Kazia Therapeutics shares are owned by company insiders. Comparatively, 57.9% of PaxMedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
PaxMedica has a consensus target price of $3.00, suggesting a potential upside of 1,150.00%. Given Kazia Therapeutics' higher possible upside, analysts plainly believe PaxMedica is more favorable than Kazia Therapeutics.
PaxMedica's return on equity of 0.00% beat Kazia Therapeutics' return on equity.
Kazia Therapeutics received 77 more outperform votes than PaxMedica when rated by MarketBeat users. However, 100.00% of users gave PaxMedica an outperform vote while only 52.35% of users gave Kazia Therapeutics an outperform vote.
Summary
Kazia Therapeutics beats PaxMedica on 7 of the 13 factors compared between the two stocks.
Get PaxMedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for PXMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PaxMedica Competitors List
Related Companies and Tools
